In short. The skin, scar and hair claims graded separately, with the size of each body of evidence stated rather than implied.
Key points
- A small study is not nothing and it is not a basis for a general claim.
- The question with a body of work this size is not whether a finding exists but whether it has been reproduced by anybody else, on a different protocol, with a different measure.
- In this subject it usually has not.
The evidence here is not one body of work. It is several, at different strengths, and grading them separately is the only honest way to describe the field.
Material properties
The most solid findings concern the material itself: that it can be prepared at the point of care from the patient’s own blood, that it coagulates into a fibrin network without an added anticoagulant, and that growth factors are released from it under laboratory conditions. These are verifiable and consistently described. They are also statements about a substance rather than about a person, and they support no clinical claim on their own.
Skin quality
Small studies report improvement in skin appearance after treatment, and the studies are limited in the ways that matter: few participants, different measures of what counts as improvement, short follow-up, and protocols that differ between them. The honest grade is limited. That is weaker than the marketing suggests and stronger than a blanket dismissal, and it is worth holding both of those in view at once.
Small studies are evidence, and they are small
A small study is not nothing and it is not a basis for a general claim. The question with a body of work this size is not whether a finding exists but whether it has been reproduced by anybody else, on a different protocol, with a different measure. In this subject it usually has not.
Scars and hair
Both areas have preliminary work and neither is settled. The studies are few, they use different preparations and different outcome measures, and the results are mixed. An important theoretical difficulty applies to both: the material is reabsorbed, so a lasting structural change has to be explained by something other than its continued presence, which places the weight of the explanation on the mechanism rather than on the material. That does not make the work wrong; it makes it early.
Under the eyes
Use in the under-eye area is reported in small studies and it is a site where the tissue is thin and the result is judged closely. The evidence is limited, the site is unforgiving, and the risk of an uneven result is higher where the skin is thin. It is a use where the gap between a plausible mechanism and a demonstrated outcome is unusually wide.
How to weigh a study you are shown
- Which preparation, made by which protocol — and is that the protocol the clinic uses?
- What was measured, over how long, and was anything compared against a group treated differently?
- Has anybody else reproduced the result with a different protocol or a different measure?
Grading by use and by protocol keeps a real material finding from being spent on a clinical claim that a different body of evidence would have to support.
Frequently asked questions
What is the strongest evidence for this preparation?
The material properties: that it can be prepared at the point of care from the patient's own blood and that it forms a fibrin network without an added anticoagulant. Those are consistently described. The clinical evidence for any aesthetic use is small and describes particular protocols rather than the treatment in general.
What does the evidence show for skin quality?
Small studies report improvement, and they are small, they differ in what they measure, and few run long enough to show whether a change persists. The grade is limited rather than established, which is weaker than the marketing but not the same as an absence of evidence.
Is there evidence for scars or hair?
There is work in both areas and it is preliminary. Studies are few, they use different preparations and different measures, and the material is reabsorbed, which makes a lasting structural effect difficult to explain. It is a reasonable area of research and it is not a settled treatment.
Risks & Limitations
- The preparation is made in the room and is not standardised, so two clinics offering the same named treatment are not necessarily offering the same material.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- There is no product authorisation and no approved indication, because there is no manufactured product to authorise.
- Growth factors measured in laboratory work are a finding about the material and not a demonstrated clinical result.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet concentrates for skin and wound indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.